Last reviewed · How we verify
DA-1229
DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes.
DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | DA-1229 |
|---|---|
| Also known as | Evogliptin |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting DPP-4, DA-1229 prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), allowing these hormones to accumulate and enhance insulin secretion in response to meals while suppressing glucagon secretion. This mechanism improves glycemic control without causing hypoglycemia when used as monotherapy.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) (PHASE2, PHASE3)
- Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State (PHASE1)
- Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD (PHASE2)
- Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction (PHASE1)
- A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin (PHASE3)
- Effect of Evogliptin on Bone Metabolism in Human (PHASE4)
- PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients (PHASE1)
- Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-1229 CI brief — competitive landscape report
- DA-1229 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI